Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate - Roche Holding (OTC:RHHBY)

Roche's Genentech reported results from the Phase 1b trial of CT-388 for obesity and type 2 diabetes. The 24-week study showed significant weight loss and improved glycemic status in participants, with mild to moderate adverse events.

Related Keywords

,Roche Holdings ,Genentech ,Carmot Therapeutics ,